Bayer: non-Hodgkin's lymphoma combo meets endpoint in trial
(CercleFinance.com) - Bayer said a combination of copanlisib and rituximab met its primary endpoint in a late-stage analysis, showing progression-free survival for patients treated with relapsed non-Hodgkin's lymphoma.
A phase III study evaluating copanlisib in combination with Roche's rituximab in patients with relapsed indolent non-Hodgkin's Lymphoma showed that the combination "significantly" prolonged progression-free survival, the German drugmaker said.
Copanlisib is an intravenous kinase inhibitor with activity against all isoforms expressed in malignant B cells.
The study enrolled 458 participants.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
A phase III study evaluating copanlisib in combination with Roche's rituximab in patients with relapsed indolent non-Hodgkin's Lymphoma showed that the combination "significantly" prolonged progression-free survival, the German drugmaker said.
Copanlisib is an intravenous kinase inhibitor with activity against all isoforms expressed in malignant B cells.
The study enrolled 458 participants.
Copyright (c) 2020 CercleFinance.com. All rights reserved.